CytoDyn responds to FDA as high court rules agency cannot guarantee drug safety
CytoDyn, Inc. has sent the FDA what the Company believes is a complete response to the agency's preliminary comments on Cytolin, a monoclonal antibody designed to restore immune function in those...
View ArticleWithdrawal of Raptiva from U.S. market
Genentech, the manufacturer of the psoriasis drug Raptiva (efalizumab), has announced that it has begun a voluntary, phased withdrawal of the product from the U.S. market.
View ArticleRituximab linked to viral brain infection
The 57-year-old lawyer in New York had handily completed the New York Times' Saturday crossword puzzle - the hardest of the week - for years. But one Saturday morning, suddenly he couldn't retrieve the...
View ArticleNew report on the psoriasis market offered by Research and Markets
Research and Markets (http://www.researchandmarkets.com/research/b8d445/commercial_insight) has announced the addition of the "Commercial Insight: Psoriasis - Intellectual property drives growth"...
View ArticleReport on autoimmune disease therapeutics in worldwide markets
Reportlinker.com announces that a new market research report is available in its catalogue. Autoimmune Disease Therapeutics
View ArticleComprehensive analysis of monoclonal antibody therapeutics market
Reportlinker.com announces that a new market research report is available in its catalogue: Reportlinker Adds Monoclonal Antibody Therapeutics 2009-2024
View ArticleReport on the future market potential for monoclonal antibodies
Reportlinker Adds Monoclonal Antibodies: Pipeline Analysis and Competitive Assessment
View ArticleDermatologists express strong interest in Stelara, despite concerns
BioTrends Research Group, Inc. released Wave 1 of its LaunchTrends(TM): Stelara report, the first in a multi-phase syndicated market research project tracking the launch of Centocor Ortho-Biotech's...
View ArticleBioTrends' Stelara second wave report finds increase in prescribing among...
BioTrends published the second wave of LaunchTrends®: Stelara, highlighting dermatology market trends at three months post launch. The report is based on 76 survey responses and 20 qualitative phone...
View ArticleLeukothera effectively treats psoriasis in humanized mouse xenograft...
Psoriasis is a persistent, long-lasting chronic skin disease affecting 2-3 percent of the world's population or more than 125 million individuals. For some, it is just a nuisance. For others, it is...
View ArticleNICE backs use of Enbrel and Raptiva to treat severe psoriasis
NICE has today issued guidance for the use of the targeted biological therapies, Enbrel (etanercept) and Raptiva (efalizumab), to treat adult patients with severe plaque psoriasis.
View ArticleEfalizumab effective in treatment of heavy psoriasis
A meta-analysis of four randomized Phase III placebo-controlled trials confirms that the injectable drug Efalizumab, a humanized therapeutic antibody designed to selectively and reversibly block the...
View ArticleFDA approves new labeling for psoriasis drug Raptiva
The U.S. Food and Drug Administration today announced labeling changes, including a Boxed Warning, to highlight the risks of life-threatening infections, including progressive multifocal...
View ArticleFDA issues warning on psoriasis drug Raptiva (efalizumab)
The U.S. Food and Drug Administration has issued a public health advisory concerning three confirmed, and one possible report of progressive multifocal leukoencephalopathy (PML), a rare brain...
View ArticleNICE backs use of Enbrel and Raptiva to treat severe psoriasis
NICE has today issued guidance for the use of the targeted biological therapies, Enbrel (etanercept) and Raptiva (efalizumab), to treat adult patients with severe plaque psoriasis.
View ArticleEfalizumab effective in treatment of heavy psoriasis
A meta-analysis of four randomized Phase III placebo-controlled trials confirms that the injectable drug Efalizumab, a humanized therapeutic antibody designed to selectively and reversibly block the...
View ArticleFDA approves new labeling for psoriasis drug Raptiva
The U.S. Food and Drug Administration today announced labeling changes, including a Boxed Warning, to highlight the risks of life-threatening infections, including progressive multifocal...
View ArticleFDA issues warning on psoriasis drug Raptiva (efalizumab)
The U.S. Food and Drug Administration has issued a public health advisory concerning three confirmed, and one possible report of progressive multifocal leukoencephalopathy (PML), a rare brain...
View ArticleCytoDyn responds to FDA as high court rules agency cannot guarantee drug safety
CytoDyn, Inc. has sent the FDA what the Company believes is a complete response to the agency's preliminary comments on Cytolin, a monoclonal antibody designed to restore immune function in those...
View ArticleWithdrawal of Raptiva from U.S. market
Genentech, the manufacturer of the psoriasis drug Raptiva (efalizumab), has announced that it has begun a voluntary, phased withdrawal of the product from the U.S. market.
View Article